Department of Dermatology, Hôpital Haut Lévêque, Avenue de Magellan, 33604, PESSAC, France.
EA2406 Histology and Molecular Pathology of Tumors, Université de Bordeaux, Bordeaux, France.
Br J Dermatol. 2015 Jun;172(6):1547-1554. doi: 10.1111/bjd.13690. Epub 2015 May 16.
Transformed mycosis fungoides (TMF) large cells may express CD30 antigen, and because of this, the differential diagnosis between CD30-rich TMF and primary cutaneous anaplastic large-cell lymphoma (cALCL) may be difficult, and especially in distinguishing cALCL associated with MF vs. CD30-rich TMF.
To find clinical, histological and molecular diagnostic features useful for differential diagnosis between cALCL and CD30-rich TMF. To analyse and compare the prognostic value of clinical and pathological factors in these two diseases.
We conducted a retrospective study (1999-2012) of 32 patients with cALCL and 34 with CD30-rich TMF, seen in reference centres of the French Study Group of Cutaneous Lymphoma. Clinical, histological and molecular features were analysed and compared to determine their diagnostic and prognostic value.
Comparison of the two groups showed that age ˃ 60 years, ≥ 5 skin lesions, early progression, absence of spontaneous regression and trunk involvement were significantly associated with the diagnosis of TMF. Abnormal T-cell phenotype and perforin expression were significantly more frequent in cALCL (both P < 0·001). Overall survival (OS) at 5 years was 77·4% for cALCL and 20·7% for CD30-rich TMF. Stage T3, ≥ 5 skin lesions, lower limb involvement for cALCL and stage T4, extracutaneous involvement, B symptoms, high levels of lactate dehydrogenase for CD30-rich TMF were associated with poor OS and progression-free survival. DUSP22 gene rearrangement had no diagnostic or prognostic value.
Clinical features and outcome are the most discriminative to differentiate the two entities. Even histological and molecular markers were not fully specific; abnormal vs. normal T-cell phenotype and perforin expression may constitute helpful tools.
转化型蕈样肉芽肿(TMF)的大细胞可能表达 CD30 抗原,因此,CD30 阳性 TMF 与原发性皮肤间变大细胞淋巴瘤(cALCL)之间的鉴别诊断可能较为困难,尤其是在区分 MF 相关的 cALCL 与 CD30 阳性 TMF 时。
寻找有助于鉴别 cALCL 和 CD30 阳性 TMF 的临床、组织学和分子诊断特征。分析和比较这两种疾病中临床和病理因素的预后价值。
我们进行了一项回顾性研究(1999-2012 年),纳入了法国皮肤淋巴瘤研究组参考中心的 32 例 cALCL 患者和 34 例 CD30 阳性 TMF 患者。分析和比较了临床、组织学和分子特征,以确定其诊断和预后价值。
两组患者的比较显示,年龄>60 岁、≥5 个皮肤病变、早期进展、无自发消退和躯干受累与 TMF 的诊断显著相关。异常 T 细胞表型和穿孔素表达在 cALCL 中更为常见(均 P<0.001)。cALCL 的 5 年总生存率(OS)为 77.4%,CD30 阳性 TMF 为 20.7%。cALCL 的不良 OS 和无进展生存率与 T 分期为 T3、≥5 个皮肤病变、下肢受累有关,而 CD30 阳性 TMF 的不良 OS 和无进展生存率与 T 分期为 T4、皮肤外受累、B 症状、乳酸脱氢酶水平升高有关。DUSP22 基因重排对诊断和预后均无价值。
临床特征和结局是区分这两种疾病的最具鉴别性的因素。即使是组织学和分子标志物也不完全具有特异性;异常 vs. 正常 T 细胞表型和穿孔素表达可能是有用的工具。